that reported in patients in Europe undergoing HD for other causes. But ESRF seems to reduce life Background. Five to 10% of heart-transplant recipients develop end-stage renal failure ( ESRF ). Little is expectancy in heart-transplant recipients. known about the outcome of these patients under renal replacement therapy.
Introduction
unsuccessful in six patients (37.5%) due to peripheral arteriopathy and they were treated with tunnelled catheters for an average 15 months without bacterial Early results after heart transplantation have been infection. Mean weight was 68.4±10 kg at onset of greatly improved with cyclosporin. However, moderate HD and 61.7±9 kg one month later. Despite this chronic renal failure often develops shortly after heart reduction in extracellular overload, one antihypertens-transplantation and exceptionally may progress to endive drug was required in 75% of patients and two drugs stage renal failure (ESRF ) [1] . There is little data in in 12.5%. One patient tolerated automated peritoneal the literature which would help guide therapeutics in dialysis (PD) for 16 months (weekly Kt/V 2.1) despite heart transplant recipients with ESRF [2] [3] [4] . We report persistent anuria. Renal transplantation (RT ) was our results in a series of patients who were treated contraindicated in eight patients because of aortoiliac with haemodialysis (HD), peritoneal dialysis (PD), or arteriopathy (n=5), poor general status (n=2), or renal transplantation (RT ). ischaemic heart disease (n=1). RT was performed in eight patients with no acute episode of heart or renal graft rejection. There were no serious infectious Subjects and methods complications. Three months after RT, mean serum creatinine was 115 mmol/l. One patient developed Between 1984 and 1992, 241 heart transplantations were post-transplant lymphoproliferative disorder 3.5 performed at the Nancy University Hospital. The standard immunosuppression protocol included cyclosporin. Among months after RT and was successfully treated with these heart-transplant recipients, ESRF developed in 16 men transplant nephrectomy. Sudden death occurred in two (6.6%) with a mean age of 52.8 years (range 39-63.4) at patients 18 and 33 months after RT. Overall patient heart transplantation. Indications for heart transplantation survival was 100, 78, and 59%, 1, 2 and 3 years after were ischaemic heart disease (50%), idiopathic cardiomyopa-HD onset respectively. Using a time-dependent vari-thy (43.75%), and valvulopathy (6.25%). One of the patients able, the Cox model analysis demonstrated that heart-was diabetic. Six of the 16 patients (37.5%) had been treated transplant recipients with ESRF have a relative risk of for chronic renal failure prior to onset of dialysis therapy death 3.2 times higher than those without ESRF (95% for ESRF, but the other 10 patients refused treatment for CI=1.3-7.8).
renal insufficiency prior to the development of ESRF.
Conclusions. HD, PD, and RT can be useful for the Dialysis began a mean 5.3 years (range 2.6-9) after heart transplantation. None of the patients had heart failure at the treatment of ESRF after heart transplantation. After onset of dialysis.
initiating HD, patient survival is nearly the same as duration of dialysis sessions. In order to evaluate the quality serum levels according to the standard recommendations [5] . years after heart transplantation. Chronic HD was Variations in weight and blood pressure were also recorded complicated by poor vascular access from the onset. as well as any antihypertensive treatment. Cyclosporin and As a long-term central catheter could not be inserted, corticosteroids were used for immunosuppression.
we opted for automated PD. Despite persistant anuria, PD was used in two patients. One developed acute poorly clearance was satisfactory: weekly peritoneal creatinine tolerated colectasia after insertion of a Tenckhoff catheter clearance=54 l; weekly Kt/V=2.1; nPCR=2.2. No which had to be ablated, and the other benefited from long-medical peritonitis developed despite immunosuppresterm PD.
sion. After 7 months of PD, this patient developed a RT was performed in eight patients; indications and strangled inguinal hernia which was cured by surgery.
outcome are reported.
The survival curve in the heart transplantation recipients After 16 months the patient developed progressively with ESRF was established with a Kaplan-Meier plot. worsening extracellular hyperhydration as the peritonSurvival rate was compared with that in heart-transplantation eum became inadapted to dialysis. recipients without ESRF who had survived more than 2 Before attempting chronic HD again, a cervical years after transplantation. A Cox model with one time-angiography identified the left subclavian vein as the dependent variable was used to account for the different only accessible vessel. Because of the anatomic remoddelays to development of ESRF [6 ] . elling, the catheter was inserted under brilliancy control by a radiologist. The procedure took more than 2 h to insert a two-way tunnelled catheter, and at the cost of Results a compressive cervical haematoma. Fourteen months later the catheter remains functional and the patient is Chronic haemodialysis in good general health. Mean duration of dialysis sessions was 4.5±0.5 h. Cuprophane, polycarbonate, or cellulose triacetate Renal transplantation membranes were used in 43.75%, 43.75% and 12.5%
An RT work-up was obtained in all patients. RT was of patients respectively. No manifestations of an allercontraindicated in eight cases due to severe aortoiliac gic reaction to the HD membrane were observed. An arteriopathy (n=5), poor general status (n=2) or arteriovenous fistula could not be created in six patients coronary artery disease (n=1). In six of these eight (37.5%) because of the poor status of the peripheral patients (75%), heart transplantation had been pervessels. A tunnelled central venous catheter was used formed for ischaemic heart disease. for dialysis in these patients for a mean 15 months A cadaver kidney was transplanted in eight patients. (range 6-24). No septic complications were observed.
Of these, only 25% had had ischaemic heart disease For these six patients, the indication for heart transprior to heart transplantation. Their mean age was plantation was ischaemic heart disease in 66%; this 56.2 years (range 43.5-68.3) at renal transplantation rate was only 30% in patients for whom a fistula could which was performed 1.2 years (range 0.06-2.5) after be created.
onset of dialysis. For the first six renal transplantations, Clinical features and laboratory results during the prophylaxis included antilymphocyte serum or OKT3 first 6 months of HD are given in Table 1 . No antihymonoclonal antibodies. All grafts functioned satisfactpertensive treatment was needed in 12.5% of patients, orily after implantation and no severe infections were one drug was used in 75%, and two drugs in 12.5%.
observed. Three months after renal transplantation, Converting enzyme inhibitor was prescribed in one mean serum creatinine was 115±11 mmol/l, mean creapatient. Human recombinant erythropoietin was used tinine clearance was 54±14 ml/min/1.73 m2. Cyclosin 12 patients. During HD, mean dosage of cyclosporin porin was given at the dose of 3.6 mg/kg/day and was 3.4 mg/kg/day. mean trough cyclosporin level was 155 ng/ml. One patient complained of pain in the kidney graft Peritoneal dialysis 3.5 months after transplantation. Renal function also declined. Ultrasonography revealed a round hilar Bronchogenic carcinoma was diagnosed in one patient 18 months after heart transplantation. Left pneumec-mass, which was removed. Pathology reported posttransplant lymphoproliferative disorder (PTLD) localtomy was required and the patient developed ESRF 8 Treatment of end-stage renal failure after heart transplantation 2907 ized in the graft. Surgical ablation of the graft was point. After beginning HD, four patients have survived for more than 4 years. The Cox model shows that the performed without modifying the immunosuppressive therapy. Immunohistochemistry showed B cells carry-risk of death in heart transplant recipients with ESRF was three times greater than that in those without ing lambda light chains on their surface associated with Epstein-Barr virus. The patient was given predni-ESRF (relative risk=3.2, 95% confidence interval= 1.3-7.8). mustine (50 mg/day) for 2 years. More than 3 years after kidney graft ablation, the patient continues HD and shows no sign of progressive PTLD. This patient Discussion is now on the waiting list for another graft.
Following this case of PTLD, we decided to reduce the dose of the immunosuppression induction protocol To our knowledge, no study has addressed the question of renal substitution therapy in heart-transplantation prior to renal transplantation. Thus, for the seventh and the eighth renal transplant patients, maintenance patients with ESRF. The main problem is to create a vascular access acceptable for long-term HD in patients levels of cyclosporin were not changed and corticosteroids were increased. These patients have not who often have peripheral arteriopathy involving the upper limbs. Iterative venepuncture for haemodynamic developed any signs of acute rejection.
catheterization or heart-graft biopsy may provoke vessel narrowing or thrombus formation in the cervical Follow-up trunks. PD is a possible alternative. A recent study Overall patient survival at 1, 2 and 3 years after onset has shown that central catheters were the leading risk of dialysis was 100, 78 and 59% respectively. In patients of septicaemia in haemodialysis patients [7] . In our whose heart transplantation had been performed for series, despite immunosuppression and a high rate of ischaemic heart disease, these survival rates were 100, catheter use, we did not encounter any infectious 62 and 62% respectively. For those with another type complications. of heart disease they were 100, 100 and 40%.
When dialysis is initiated, patients are in a state of Renal graft survival at 1 year was 83.3%, not taking major extracellular hyperhydration as revealed by high into account the one case of sudden death the day of blood pressure and weight loss greater than 9% comrenal transplantation. This patient had refused routine pared with the initial weight. Progressive depletion coronarography. Coronarography was performed in appears to be well tolerated by the heart graft. In one the seven other renal-transplantation candidates to recently reported series, it was shown that mean cardiac assess the heart graft. Two patients with no evidence index was unchanged before onset of HD and one year of lesions on the coronarograms died of cardiogenic later [3] . In 1996, among the 120 patients undergoing shock and sudden death 18 and 33 months respectively haemodialysis in our unit, 66% had no antihypertensive after renal transplantation, possibly due to accelerated regimen, 28% were taking one antihypertensive drug, heart rejection. No autopsies were performed. and 6% were taking two. In our heart-transplantation Survival in heart transplant recipients with ESRF recipients with ESRF, these figures were 12.5, 75 and was 53% 10 years after heart transplantation 12.5% respectively. No data were available concerning (Figure 1 ). Seven patients had died at the study end-the prevalence of hypertension in heart-transplant patients without ESRF. The high rate of hypertension is probably a consequence of the lack of heart graft innervation and maintained cyclosporin therapy [8] .
Weight gain between dialysis sessions is considerable, over 2 kg. This is possibly due to stimulation of thirst by the renin-angiotensin system [1, 8] or to poor patient compliance to fluid intake restriction. The quantity of dialysis delivered to our patients was estimated by Kt/V. The figures obtained during the first 6 months of dialysis were comparable with those obtained in our population of 120 HD patients without heart transplantation: 1.36±0.3. Problems with the vascular access do not apparently compromise correct dialysis. This was confirmed by a gain in lean body mass 6 months after dialysis onset and by improved general health.
The Stanford team did not give any details as to why a kidney graft was not used in five of their 14 heart-transplantation patients [4] . In our experience, renal transplantation was mainly contraindicated by severe aortoiliac atheroma found in those patients with Fig. 1 . Kaplan-Meier estimates of survival for heart-transplant ischaemic heart disease prior to heart transplantation. recipients with ESRF (n=16). (Number of patients at risk indicated by parentheses.).
The long-term survival of heart transplant recipients
